MX2012000572A - Moduladores del receptor 5-hidroxi triptamina 3 (5-ht3), metodos para su realización y uso de los mismos. - Google Patents
Moduladores del receptor 5-hidroxi triptamina 3 (5-ht3), metodos para su realización y uso de los mismos.Info
- Publication number
- MX2012000572A MX2012000572A MX2012000572A MX2012000572A MX2012000572A MX 2012000572 A MX2012000572 A MX 2012000572A MX 2012000572 A MX2012000572 A MX 2012000572A MX 2012000572 A MX2012000572 A MX 2012000572A MX 2012000572 A MX2012000572 A MX 2012000572A
- Authority
- MX
- Mexico
- Prior art keywords
- making
- methods
- receptor modulators
- vomiting
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Addiction (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a moduladores del receptor de 5-HT3 novedosos. Estos compuestos se usan en el tratamiento de varios trastornos incluyendo náuseas y vómitos inducidos por quimioterapia, náuseas y vómitos postoperatorios y síndrome del intestino irritable. Los métodos para realizar estos compuestos también se describen en la presente invención.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22536809P | 2009-07-14 | 2009-07-14 | |
PCT/US2010/040617 WO2011008572A2 (en) | 2009-07-14 | 2010-06-30 | 5-ht3 receptor modulators, methods of making, and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012000572A true MX2012000572A (es) | 2012-05-08 |
Family
ID=43450096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012000572A MX2012000572A (es) | 2009-07-14 | 2010-06-30 | Moduladores del receptor 5-hidroxi triptamina 3 (5-ht3), metodos para su realización y uso de los mismos. |
Country Status (13)
Country | Link |
---|---|
US (2) | US8710046B2 (es) |
EP (1) | EP2459563A4 (es) |
JP (1) | JP5663572B2 (es) |
KR (1) | KR20120104512A (es) |
CN (1) | CN102510862A (es) |
AU (1) | AU2010273732A1 (es) |
BR (1) | BR112012000788A2 (es) |
CA (1) | CA2767233A1 (es) |
IL (1) | IL217297A0 (es) |
MX (1) | MX2012000572A (es) |
NZ (1) | NZ597613A (es) |
SG (1) | SG177523A1 (es) |
WO (1) | WO2011008572A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101653707B1 (ko) | 2008-05-29 | 2016-09-02 | 알바니 몰레큘라 리써치, 인크. | 5-ht3 수용체 조절제, 이의 제조 방법, 및 그의 용도 |
JP6433922B2 (ja) * | 2013-02-27 | 2018-12-05 | アレイ バイオファーマ、インコーポレイテッド | インダゾール誘導体の調製に使用するための中間体およびその調製方法 |
WO2015113057A1 (en) | 2014-01-27 | 2015-07-30 | Allergan, Inc. | Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation |
CN111825702A (zh) * | 2019-04-22 | 2020-10-27 | 成都科岭源医药技术有限公司 | 一种氮杂*并吲唑类衍生物及其制备方法和用途 |
CN112390799B (zh) * | 2019-08-16 | 2022-04-29 | 科岭源生物科技(深圳)有限公司 | 一种含氮杂环类5-ht3受体调节剂及其制备方法和用途 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3642821A (en) | 1969-11-03 | 1972-02-15 | Upjohn Co | Tetrahydropyrrolobenzodiazepines |
US3734919A (en) | 1969-11-03 | 1973-05-22 | Upjohn Co | 4,5-di-hydropyrrolo(3,2,1-jk)(1,4)benzodiazepin-7(6h)-ones and 4,5-di-hydropyrrolo(1,2,3-ef)(1,5)benzodiazepin-6(7h)-ones |
CH575397A5 (es) | 1971-11-09 | 1976-05-14 | Basf Ag | |
GB8525844D0 (en) | 1985-10-19 | 1985-11-20 | Beecham Group Plc | Compounds |
NZ236225A (en) * | 1989-11-28 | 1992-09-25 | Syntex Inc | Azabicyclic-substituted isoquinoline derivatives, intermediates and pharmaceutical compositions |
JP2699794B2 (ja) | 1992-03-12 | 1998-01-19 | 三菱化学株式会社 | チエノ〔3,2−b〕ピリジン誘導体 |
CH689139A5 (de) | 1995-04-03 | 1998-10-30 | Cerbios Pharma Sa | Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung. |
US6120794A (en) | 1995-09-26 | 2000-09-19 | University Of Pittsburgh | Emulsion and micellar formulations for the delivery of biologically active substances to cells |
JPH10508322A (ja) | 1995-10-12 | 1998-08-18 | スーパーゲン,インコーポレイティド | 5βステロイドのリポソーム配合物 |
UY25225A1 (es) | 1997-10-29 | 2000-12-29 | Smithkline Beecham Plc | Derivados de pleuromutilina utiles como agentes antimicrobianos |
EA200001109A1 (ru) | 1998-05-20 | 2001-06-25 | ДЗЕ ЛИПОСОМ КОМПАНИ, Инк. | Новые частицы, композиция на их основе и способ лечения с их применением |
BR9916495A (pt) | 1998-12-22 | 2001-09-04 | Novartis Pharma Gmbh | Uso de 5ht3-receptor-antagonistas |
CA2373920A1 (en) | 1999-06-15 | 2000-12-21 | Wei Deng | Substituted heterocycle fused gamma-carbolines |
US6743785B2 (en) | 1999-12-16 | 2004-06-01 | Eli Lilly And Company | Agents and methods for the treatment of proliferative diseases |
TWI256314B (en) | 2000-02-09 | 2006-06-11 | Mitsubishi Pharma Corp | Preventive-therapeutical medicament for gastroesophageal reflux disease |
PT1501534E (pt) | 2002-05-07 | 2006-09-29 | Ferring Bv | Formulacoes farmaceuticas |
CN101018550A (zh) * | 2004-07-14 | 2007-08-15 | 诺瓦提斯公司 | Dpp-iv抑制剂与调节5-ht3和/或5-ht4受体的化合物的组合 |
MX2007010063A (es) | 2005-02-17 | 2008-01-16 | Albany Molecular Res Inc | Benzoxazol-carboxamidas para el tratamiento de la naucea y el vomito inducidos por quimioterapia y sindrome del intestino irritable con diarrea predominante. |
EP1904069B1 (en) * | 2005-07-15 | 2018-06-13 | Albany Molecular Research, Inc. | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
GB0515090D0 (en) | 2005-07-22 | 2005-08-31 | Birmingham Res & Dev Ltd | Novel epilepsy treatment |
WO2007019078A2 (en) | 2005-08-03 | 2007-02-15 | Merck & Co., Inc. | Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease |
FR2901703B1 (fr) | 2006-05-31 | 2012-12-07 | Galderma Res & Dev | Utilisation de zatosetron pour le traitement de la rosacee, et compositions pharmaceutiques |
MX2009001494A (es) | 2006-08-07 | 2009-04-23 | Albany Molecular Res Inc | 2-aminobenzoxazol carboxamidas como moduladores 5ht3. |
US7553846B2 (en) | 2006-08-07 | 2009-06-30 | Albany Molecular Research, Inc. | 2-alkylbenzoxazole carboxamides as 5-HT3 modulators |
US20080153863A1 (en) | 2006-12-22 | 2008-06-26 | Caterina Bissantz | Spiropiperidine derivatives |
KR20090101370A (ko) * | 2007-01-10 | 2009-09-25 | 알바니 몰레큘라 리써치, 인크. | 5-피리디논 치환된 인다졸 |
KR101653707B1 (ko) * | 2008-05-29 | 2016-09-02 | 알바니 몰레큘라 리써치, 인크. | 5-ht3 수용체 조절제, 이의 제조 방법, 및 그의 용도 |
-
2010
- 2010-06-30 MX MX2012000572A patent/MX2012000572A/es active IP Right Grant
- 2010-06-30 US US13/384,050 patent/US8710046B2/en not_active Expired - Fee Related
- 2010-06-30 NZ NZ597613A patent/NZ597613A/en not_active IP Right Cessation
- 2010-06-30 CN CN2010800418347A patent/CN102510862A/zh active Pending
- 2010-06-30 JP JP2012520659A patent/JP5663572B2/ja not_active Expired - Fee Related
- 2010-06-30 BR BR112012000788A patent/BR112012000788A2/pt not_active IP Right Cessation
- 2010-06-30 EP EP10800312A patent/EP2459563A4/en not_active Withdrawn
- 2010-06-30 SG SG2012000782A patent/SG177523A1/en unknown
- 2010-06-30 KR KR1020127003158A patent/KR20120104512A/ko not_active Application Discontinuation
- 2010-06-30 AU AU2010273732A patent/AU2010273732A1/en not_active Abandoned
- 2010-06-30 WO PCT/US2010/040617 patent/WO2011008572A2/en active Application Filing
- 2010-06-30 CA CA2767233A patent/CA2767233A1/en not_active Abandoned
-
2011
- 2011-12-29 IL IL217297A patent/IL217297A0/en unknown
-
2014
- 2014-03-10 US US14/203,033 patent/US9045501B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2767233A1 (en) | 2011-01-20 |
SG177523A1 (en) | 2012-02-28 |
EP2459563A4 (en) | 2013-01-16 |
WO2011008572A2 (en) | 2011-01-20 |
US20120270857A1 (en) | 2012-10-25 |
CN102510862A (zh) | 2012-06-20 |
BR112012000788A2 (pt) | 2016-02-23 |
JP2012533544A (ja) | 2012-12-27 |
NZ597613A (en) | 2014-01-31 |
US20140234443A1 (en) | 2014-08-21 |
EP2459563A2 (en) | 2012-06-06 |
KR20120104512A (ko) | 2012-09-21 |
US9045501B2 (en) | 2015-06-02 |
US8710046B2 (en) | 2014-04-29 |
AU2010273732A1 (en) | 2012-02-09 |
IL217297A0 (en) | 2012-02-29 |
WO2011008572A3 (en) | 2011-06-03 |
JP5663572B2 (ja) | 2015-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009155054A3 (en) | 5-ht3 receptor modulators, methods of making, and use thereof | |
MX345909B (es) | Anticuerpos anti-fgfr3 y métodos que los utilizan. | |
MX2012007507A (es) | Compuestos de heteroarilo y usos de los mismos. | |
MY181898A (en) | Heterocyclic compounds and uses thereof | |
MX2011007930A (es) | Conjugados de insulina cristalina. | |
MX2009008430A (es) | Anticuerpos anti-robo4 y sus usos. | |
WO2009108860A8 (en) | Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders | |
MY159362A (en) | Crystalline forms of dimethoxy docetaxel and methods for preparing the same | |
MY173616A (en) | Compositions and methods for lowering triglycerides | |
TW200801021A (en) | Imidazolothiazole compounds for the treatment of disease | |
AU2016219704A1 (en) | Anti-Notch1 antibodies | |
MX2012003539A (es) | Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac). | |
AU2010236734A8 (en) | 5-HT4 receptor agonist compounds for treatment of cognitive disorders | |
UA96424C2 (ru) | Циклопропил амины как модуляторы н3 рецепторов гистамина | |
PH12015501955B1 (en) | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases | |
UA102857C2 (en) | Quinuclidine carbonate derivatives and use thereof | |
MX2011010012A (es) | NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS. | |
EA201070059A1 (ru) | Композиции, содержащие ингибиторы триптофангидроксилазы | |
MX2010006206A (es) | Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
WO2012003501A3 (en) | Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives | |
MX2012000572A (es) | Moduladores del receptor 5-hidroxi triptamina 3 (5-ht3), metodos para su realización y uso de los mismos. | |
NO20083751L (no) | Metoder for behandling av kognitive og andre sykdommer | |
IN2012DN03844A (es) | ||
UA103468C2 (ru) | Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н3 | |
EP2576575A4 (en) | PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, THEIR METHODS OF MANUFACTURE AND USES THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |